iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Rehman, Ishtiaq ^a   Evans, Caroline A ^a,b   Glen, Adam ^a   Cross, Simon S ^b   Eaton, Colby L ^a   Down, Jenny ^a   Pesce, Giancarlo ^a   Phillips, Joshua T ^c   Yen, Ow Saw ^b   Thalmann, George N ^d   Wright, Phillip C ^b   Hamdy, Freddie C ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ELONGATION FACTOR 1ALPHA; EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA 1 PROTEIN; PROTEIN EEF1A1; UNCLASSIFIED DRUG; EEF1A1 PROTEIN, HUMAN; EEF1A2 PROTEIN, HUMAN; ELONGATION FACTOR 1; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EUKARYOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; MALE; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PATIENT MONITORING; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TUMOR CELL; BLOOD; BONE TUMOR; CANCER GRADING; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; METASTASIS; OSTEOSARCOMA; PATHOLOGY; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR CELL CULTURE; WESTERN BLOTTING;

EUKARYOTA;

AGED; BLOTTING, WESTERN; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM GRADING; OSTEOSARCOMA; PEPTIDE ELONGATION FACTOR 1; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84857068469     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030885     Document Type: Article

References (53)

1. Damber JE, Aus G, (2008) Prostate cancer. Lancet 371: 1710-1721.
2. Gronberg H, (2003) Prostate cancer epidemiology. Lancet 361: 859-864.
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439.
4. Zhu X, van Leeuwen PJ, Bul M, Bangma CH, Roobol MJ, et al. (2011) Identifying and characterizing "escapes"- men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam). Int J Cancer 129: 2847-2854.
5. LaSpina M, Haas GP, (2008) Update on the diagnosis and management of prostate cancer. Can J Urol 15 (Suppl 1): 3-13; discussion 13.
6. Lilja H, Ulmert D, Vickers AJ, (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8: 268-278.
7. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, et al. (2005) Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 48: 1031-1041.
8. Anderson NL, Anderson NG, (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1: 845-867.
9. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, et al. (2008) Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 7: 1963-1973.
10. Sun W, Wu S, Wang X, Zheng D, Gao Y, (2005) An analysis of protein abundance suppression in data dependent liquid chromatography and tandem mass spectrometry with tryptic peptide mixtures of five known proteins. Eur J Mass Spectrom (Chichester, Eng) 11: 575-580.
11. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, et al. (2009) 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 8: 942-957.
12. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, et al. (2003) Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 3: 422-432.
13. Liu T, Qian WJ, Mottaz HM, Gritsenko MA, Norbeck AD, et al. (2006) Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics 5: 2167-2174.
14. Glen A, Evans CA, Gan CS, Cross SS, Hamdy FC, et al. (2010) Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. Prostate 70: 1313-1332.
15. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, et al. (2008) iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res 7: 897-907.
16. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, et al. (2006) Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 5: 1143-1154.
17. Cross SS, Hamdy FC, Deloulme JC, Rehman I, (2005) Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46: 256-269.
18. Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, et al. (2004) Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 35: 1385-1391.
19. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, et al. (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2: 1627-1636.
20. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581.
21. Bandow JE, (2010) Comparison of protein enrichment strategies for proteome analysis of plasma. Proteomics 10: 1416-1425.
22. Boylan KL, Andersen JD, Anderson LB, Higgins L, Skubitz AP, (2010) Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum. Proteome Sci 8: 31.
23. Pham TK, Roy S, Noirel J, Douglas I, Wright PC, et al. (2010) A quantitative proteomic analysis of biofilm adaptation by the periodontal pathogen Tannerella forsythia. Proteomics 10: 3130-3141.
24. Ow SY, Salim M, Noirel J, Evans C, Rehman I, et al. (2009) iTRAQ underestimation in simple and complex mixtures: The good, the bad and the ugly. J Proteome Res.
25. Elias JE, Gygi SP, (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4: 207-214.
26. Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, et al. (2004) S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 91: 739-744.
27. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, et al. (2003) PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 31: 334-341.
28. Noirel J, Evans C, Salim M, Mukherjee J, Ow SY, et al. (2011) Methods in Quantitative Proteomics: Setting iTRAQ on the Right Track. Current Proteomics 8: 17-30.
29. Qingyi Z, Lin Y, Junhong W, Jian S, Weizhou H, et al. (2009) Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach. Cancer Invest 27: 794-801.
30. Zhu G, Yan W, He HC, Bi XC, Han ZD, et al. (2009) Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1 alpha expression. Mol Med 15: 363-370.
31. Gross M, Top I, Laux I, Katz J, Curran J, et al. (2007) Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 13: 1979-1986.
32. Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, et al. (2010) C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol.
33. Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH, (2000) Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 56: 267-272.
34. Cima I, Schiess R, Wild P, Kaelin M, Schuffler P, et al. (2011) Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci U S A.
35. Yoshimura S, Tamaoki N, Ueyama Y, Hata J, (1978) Plasma protein production by human tumors xenotransplanted in nude mice. Cancer Res 38: 3474-3478.
36. Mbeunkui F, Metge BJ, Shevde LA, Pannell LK, (2007) Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 6: 2993-3002.
37. Ward AM, Cooper EH, Houghton AL, (1977) Acute phase reactant proteins in prostatic cancer. Br J Urol 49: 411-418.
38. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, et al. (2005) Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51: 695-707.
39. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, et al. (2004) Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 64: 347-355.
40. Drake RR, White KY, Fuller TW, Igwe E, Clements MA, et al. (2009) Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics 72: 907-917.
41. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, et al. (2006) beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66: 9108-9116.
42. Malik G, Knowles LM, Dhir R, Xu S, Yang S, et al. (2010) Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res 70: 4327-4334.
43. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, et al. (2007) Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 13: 7370-7379.
44. Sun Y, Lin J, Katz AE, Fisher PB, (1997) Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res 57: 18-23.
45. Shen R, Su ZZ, Olsson CA, Fisher PB, (1995) Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci U S A 92: 6778-6782.
46. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, et al. (2004) Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 21: 399-408.
47. Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, et al. (2009) A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics 73: 352-356.
48. Burgess EF, Ham AJ, Tabb DL, Billheimer D, Roth BJ, et al. (2008) Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes. Proteomics Clin Appl 2: 1223.
49. Zhang WM, Finne P, Leinonen J, Stenman UH, (2000) Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Scand J Clin Lab Invest Suppl 233: 51-58.
50. Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG, (2004) Are multiple markers the future of prostate cancer diagnostics? Clin Biochem 37: 519-528.
51. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, et al. (2009) Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol 181: 1407-1414.
52. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
53. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD, (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438.